Summary.-The immunotherapeutic value of tumour extracts or B.C.G. in preventing either the occurrence of primary tumours or the recurrence of tumours in surgically resected animals has been examined. A transplantable methylcholanthrene induced tumour in DBA/2J mice was used. Neither tumour extract nor chemically modified extract was effective in preventing tumour growth in immunized animals, even though the mice demonstrated measurable levels of cell mediated tumour immunity at the time of tumour challenge. The frequency of tumour recurrence after resection of small tumours (about 1-0 g) was significantly lowered by treatment of the mice with a combination of B.C.G. and either modified or unmodified tumour extract. The frequency of recurrence after resection of large tumours (about 2-5 g) was not affected by any form of immunotherapy although the survival time of treated animals was significantly prolonged. The immunological status of animals with small and large tumours was examined and it was shown that mice with 1-0 g tumours have unimpaired mitogen responsiveness and measurable tumour specific immunity, whereas mice bearing large tumours (2.5 g) have a markedly impaired immune system.
by treatment of the mice with a combination of B.C.G. and either modified or unmodified tumour extract. The frequency of recurrence after resection of large tumours (about 2-5 g) was not affected by any form of immunotherapy although the survival time of treated animals was significantly prolonged. The immunological status of animals with small and large tumours was examined and it was shown that mice with 1-0 g tumours have unimpaired mitogen responsiveness and measurable tumour specific immunity, whereas mice bearing large tumours (2.5 g) have a markedly impaired immune system. IMMUNIZATION of experimental animals against challenge with tumour inducing doses of tumour cells has had varied success in a number of tumour systems. It has been generally observed that the greatest success with this type of protocol has involved the use of tumour cells, killed or inactivated with agents such as irradiation or mitomycin C (Alexander, Connell and Mikulska, 1966; Lin, Huber and Murphy, 1969; Revesz, 1960; Baldwin, Embleton and Moore, 1973) . In general, attempts to immunize animals against tumour cell challenge with extracts from tumour cells have been unsuccessful, even when such extracts have been shown to contain tumour specific transplantation antigens .
Recently, the use of nonspecific immunostimulants such as B.C.G., either 20 alone or in combination with inactivated tumour cells, as a method of treatment of established tumours has aroused considerable interest. Several studies have demonstrated regression of established tumours by administration of B.C.G. alone to guinea-pigs (Zbar et al., 1972; Zbar and Tanaka, 1971) or B.C.G. in combination with autochthonous tumour cells treated with neuraminidase and mitomycin C to mice (Simmons and Rios, 1971) . However, another study has shown that while B.C.G. treatment at the time of grafting of a polyoma tumour in rats prevented tumour take, similar treatment of established tumours, or tumours which had been incompletely excised, caused enhanced tumour growth (Bansal and Sjogren, 1973) .
The relationship between the immune system of an individual and tumour growth is obviously complex, and may apparently be either beneficial or detrimental depending on a number of variables. In particular, the relative effects of circulating antibody versus sensitized cells on tumour growth remain to be clarified. However, Rouse, Rollinghoff and Warner (1973) (Parish, 1971a, b; Shirrmacher and Wigzell, 1972; Thompson et al., 1972) Acetoacetylation.-Tumour extracts were acetoacetylated according to the procedure followed by Parish (1971a) . That the modified extract no longer cross-reacted with unmodified extract at the humoral level, but continued to cross-react at the cell mediated level was established by immunizing guineapigs with the native tumour extract and subsequently skin testing them with both native and modified extracts. Guinea-pigs were immunized with 3-0 mg of tumour extract injected intramuscularly in a total volume of 0-3 ml of 50% complete Freund's adjuvant (CFA). Ten days later their flanks were shaved and they were skin tested with 50-0 ,ug of both unmodified and modified extract in a total of 01l ml saline. All the guinea-pigs so tested gave classic immediate and delayed skin reactions to the unmodified extract but only delayed responses to the acetoacetylated preparations.
Immunization.-Mice were immunized to either the tumour extract or its acetoacetylated derivative by 6 subcutaneous injections containing 50-0 Hg of protein in 50% v/v CFA in 0-2 ml at weekly intervals.
Control mice were injected with 0-2 ml of 50% CFA in saline. Following immunization, the animals were challenged with either 104 or 105 viable tumour cells, and were examined twice a week for the presence and the rate of growth of tumours. Nonimmunized (normal) mice were controls throughout.
In some experiments it was essential to obtain control mice which were immune to tumour cell challenge. These immune mice were obtained by inducing tumours with a cell inoculum and resecting them. Those mice not developing tumour recurrences were invariably resistant to challenge with 105 tumour cells, and these animals were used as immune controls.
Tumour resection and immunotherapy.-Mice were immunized with a single subcutaneous injection of 50 0 ,ug of PPD (Connaught Medical Laboratories, Toronto, Ontario) in 50% v/v CFA (Difco Laboratories, Detroit, Michigan) in a total volume of 0-2 ml. Two weeks later all animals were injected subcutaneously in the right abdominal side with 105 tumour cells, a dose which produces 100% takes within 7-12 days.
This study involved, in part, an evaluation of post-surgical immunotherapy at different stages of tumour growth. Two main experiments were carried out, the only variable being the size of tumour at time of resection, so that in the 2 experiments tumours were removed when they had reached either about 1-0 g or 2-5 g. Mice were partially anaesthetized with Nembutal (pentobarbitone sodium) and were maintained under ether anaesthesia during surgical removal of the tumours. Before surgery the animals were randomized and divided into the desired number of groups. Immediately after surgery, and at weekly intervals thereafter, the mice were treated in one of the following ways: Group A, 0-2 ml of PBS (0.01 mol/l phosphate buffered saline pH 7.5); Group B, 1-0 mg of B.C.G. (Connaught Medical Laboratories, Toronto, Ontario) in 0-2 ml of PBS; Group C, 1-0 mg of B.C.G. plus 50-0 ug of tumour extract in 0-2 ml of PBS; Group D, 1-0 mg of B.C.G. plus 50-0 ,ug of modified tumour extract in 0-2 ml of PBS; Group E, 50-0 ,ug of tumour extract in 0-2 ml of PBS; Group F, 50-0 Htg of modified tumour extract in 0-2 ml of PBS.
The B.C.G. (viable freeze dried organisms) was made up in PBS immediately before use. The appropriate injections were given subcutaneously in the abdomen. The animals were maintained on antibiotics (terramycin, animal formula, Pfizer) after surgery. The mice were observed for 7 weeks after surgery and the time of tumour recurrence and the time of death following recurrence were noted.
Assessment of cell mediated immunity.-Tumour specific cell mediated immunity was measured by the colony inhibition technique developed by Hellstrom and Hellstrom (1971) . These tests were carried out on immunized animals at several stages during tumour growth, 5 days after resection and on animals which did not develop tumour recurrences after resection. Cultured tumour cells were harvested from 100 x 20 mm petri plates by trypsinization (2-0 ml of 0-25% typsin for 10 min at 37°C). Foetal calf serum was added to stop enzyme action and the cells were washed once by centrifugation in PBS. The cells were counted and made up to a concentration of 200 cells/ml in RPMI-1640 + 10°heat inactivated foetal calf serum. Then 1-5 ml of the suspension was dispensed to a number of 60 x 15 mm plastic Falcon petri plates and incubated overnight to allow cell attachment. The following morning the medium was removed and 5 x 106 spleen cells from test animals in 1-5 ml of RPMI-1640 without serum were added to each plate. The following day an additional 1-5 ml of medium containing 20% FCS was added to each plate. The plates were incubated for 7-8 days from the time of addition of the spleen cells, after which time the medium was removed and each plate was rinsed 3 times with saline. Colonies were stained for 30 min with 1-5 ml of crystal violet (1 g/100 ml of methanol). Excess stain was washed off with tap water and the plates were dried, after which macroscopical enumeration of colonies was carried out.
Mitogen stimulation.-The ability of mouse spleen cells to respond to the mitogens concanavalin A (ConA) and bacterial lipopolysaccharide (LPS) was assessed at various times, using a microtitre culturing procedure which has been described fully elsewhere (Whitney, Levy and Smith, 1974 immunized mice were not protected against tumour challenge, they exhibited significant cell mediated immunity specific for the tumour cells, as measured by colony inhibition (Table I) . Results from animals immunized with unmodified tumour extract (not shown) were essentially the same as those shown for modified extracts in the Fig. and Table I . Immunotherapy experiments The effects of the various types of immunotherapy on mice from which tumours had been resected when they reached approximately 1.0 g are summarized in Table II . It can be seen that while B.C.G. alone did not significantly reduce the frequency of tumour recurrence compared with untreated controls, the combined therapy using B.C.G. with either unmodified or modified tumour extracts (Groups C and D) did. Neither of the tumour extracts on their own reduced the frequency of tumour recurrence significantly, nor in any instance was the survival time increased as a -result of immunotherapy. It was clear 50 that in these animals, combined specific and nonspecific immunostimulation produced the most beneficial effect. The results obtained from a similar experiment, in which tumour sizes were about 2-5 g at the time of resection are summarized in Table III : Data compiled only on mice developing recurrences.
seen that immunotherapy had a rather different effect in these animals. The recurrence frequency in all of the treated groups was not significantly different from that of the controls. However, the mean survival times of all the animals on immunotherapy were significantly longer than the mean survival time of control animals. In both experiments, all mice not developing recurrences after 4 weeks were found to be resistant to challenge with 105 tumour cells.
Immune status of tumour bearing animals It was felt that the different effects of immunotherapy seen in the 2 groups of mice might be related to the immunological status of animals at the time of tumour resection. Consequently representative mice with tumours of approximately 1-0 g and 2-5 g were examined with respect to their immunological competence before surgery and 5 days following tumour resection. Test animals were sacrificed and their spleen cells tested for mitogen response to both ConA and LPS as well as for specific cell mediated immunity by the colony inhibition test.
In each case the responses of test mice were measured in comparison with normal non-immune mice. The results are shown in Tables IV, V and VI. As can be seen (Table IV) the mitogen responses in animals with the smaller tumours were not significantly lower than those of nonimmune controls. However, mice bearing larger tumours had no response to either ConA or LPS at the time of resection, Baldwin, Price and Robins (1973) implicate tumour associated antigens and/or antigen-antibody complexes in blocking cell mediated tumour immunity. These observations are not incompatible with the results discussed above.
The efficiency of either nonspecific immunostimulation with B.C.G. or specific immunotherapy with modified and unmodified tumour extracts in preventing tumour recurrence after resection was investigated. A number of clear observations were made. Significant reductions in the frequency of tumour recurrence in mice with tumours of between 075 and 1-0 g were obtained with immunotherapy utilizing a combination of B.C.G. and either modified or unmodified tumour extract. In protocols utilizing only one form of immunostimulation, the modified tumour extract was more efficient than either the unmodified extract or B.C.G.
in preventing tumour recurrence (P < 0.2) but none of these test groups were significantly different from control animals. Animals in this experimental group demonstrated specific tumour immunity at the time of surgery and 5 days thereafter, and their spleen cells demonstrated a normal mitogen response to ConA and LPS.
Mice with large tumours (about 2-5 g) responded quite differently to immunotherapy, in that no procedure was effective in significantly reducing the frequency of tumour recurrence. However, all immunotherapy treatments significantly prolonged the life of the tumour bearing animals. These animals at the time of surgery demonstrated essentially no tumour specific immunity, and their mitogen responses were minimal (Table IV) . Five days after surgery, there was apparently some recovery of immunological status in these animals although mitogen responses were still significantly lower than untreated controls and significant tumour specific immunity was noted in only 2 of the 5 animals so tested.
It would appear that the immunological status of the animal at the time of tumour resection is a primary factor in determining whether immunotherapy will be effective in preventing tumour recurrence. It would also appear that while tumour extracts are not effective in primary immunization of animals against tumour cell challenge, they are effective, under appropriate conditions, as immunotherapeutic agents in preventing tumour recurrence. The reasons for this latter observation are not clear at this time and require further research.
